Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has initiated the human trial of ARO-ALK7, a novel RNA interference (RNAi) ...

A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Momentum Continues with Presentations at ASCO and ESMO Imunon, Inc.

Rigorous study design and analytical standards are required to generate reliable findings in healthcare from artificial intelligence (AI) research. One crucial but often overlooked aspect is the ...

For more information about Syncromune, please visit www.syncromune.com.

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

| When clinical trial steps are managed separately, the study suffers from compounded delays. Discover proven solutions from ...

As shown in table 2, both OS and CBR values were in line or higher than those reported in the treatment arm of the ASCENT ...

Auron Therapeutics begins patient dosing in phase 1 trial of AUTX-703 in advanced hematologic malignancies: Newton, Massachusetts Monday, June 2, 2025, 16:00 Hrs [IST] Auron Thera ...

A novel triple reuptake inhibitor is efficacious and ‘clinically meaningful’ for adult attention-deficit/hyperactivity ...

The findings suggest that "the heightened focus on alternative endpoints, now representing the most common primary endpoint, ...